company background image
ONCR logo

Oncorus OTCPK:ONCR Stock Report

Last Price

US$0.13

Market Cap

US$3.3m

7D

26.0%

1Y

-58.0%

Updated

03 Jan, 2024

Data

Company Financials

ONCR Stock Overview

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients.

ONCR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Oncorus, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oncorus
Historical stock prices
Current Share PriceUS$0.13
52 Week HighUS$0.47
52 Week LowUS$0.01
Beta1.95
11 Month Change500.00%
3 Month Change427.20%
1 Year Change-58.00%
33 Year Change-99.63%
5 Year Changen/a
Change since IPO-99.21%

Recent News & Updates

Recent updates

Oncorus GAAP EPS of -$0.74 misses by $0.02

Aug 04

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oct 14
We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic

Jul 09

Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans

May 05
Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans

What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?

Feb 26
What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?

Oncorus: Buy On A Dip, Potential Already Priced In At Current Levels

Feb 02

Oncorus to build viral immunotherapy clinical manufacturing facility in U.S.

Jan 04

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Jan 04
We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus reports Q3 results

Nov 11

Shareholder Returns

ONCRUS BiotechsUS Market
7D26.0%0.2%-2.1%
1Y-58.0%12.5%19.0%

Return vs Industry: ONCR underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: ONCR underperformed the US Market which returned 22.4% over the past year.

Price Volatility

Is ONCR's price volatile compared to industry and market?
ONCR volatility
ONCR Average Weekly Movement210.0%
Biotechs Industry Average Movement10.6%
Market Average Movement5.9%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: ONCR's share price has been volatile over the past 3 months.

Volatility Over Time: ONCR's weekly volatility has increased from 101% to 210% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201564Craig Jalbertwww.oncorus.com

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.

Oncorus, Inc. Fundamentals Summary

How do Oncorus's earnings and revenue compare to its market cap?
ONCR fundamental statistics
Market capUS$3.29m
Earnings (TTM)-US$90.54m
Revenue (TTM)n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ONCR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$90.54m
Earnings-US$90.54m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.47
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio66.0%

How did ONCR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.